- Home
- HYI vs TVRD Comparison
HYI vs TVRD Comparison
Compare HYI & TVRD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HYI
- TVRD
- Stock Information
- Founded
- HYI 2010
- TVRD 2017
- Country
- HYI United States
- TVRD United States
- Employees
- HYI N/A
- TVRD N/A
- Industry
- HYI Investment Managers
- TVRD Biotechnology: Pharmaceutical Preparations
- Sector
- HYI Finance
- TVRD Health Care
- Exchange
- HYI Nasdaq
- TVRD Nasdaq
- Market Cap
- HYI 264.3M
- TVRD 246.5M
- IPO Year
- HYI N/A
- TVRD N/A
- Fundamental
- Price
- HYI $11.79
- TVRD $24.50
- Analyst Decision
- HYI
- TVRD Strong Buy
- Analyst Count
- HYI 0
- TVRD 2
- Target Price
- HYI N/A
- TVRD $52.00
- AVG Volume (30 Days)
- HYI 50.6K
- TVRD 47.8K
- Earning Date
- HYI 01-01-0001
- TVRD 05-13-2025
- Dividend Yield
- HYI 9.59%
- TVRD N/A
- EPS Growth
- HYI N/A
- TVRD N/A
- EPS
- HYI N/A
- TVRD N/A
- Revenue
- HYI N/A
- TVRD N/A
- Revenue This Year
- HYI N/A
- TVRD N/A
- Revenue Next Year
- HYI N/A
- TVRD N/A
- P/E Ratio
- HYI N/A
- TVRD N/A
- Revenue Growth
- HYI N/A
- TVRD N/A
- 52 Week Low
- HYI $10.99
- TVRD $8.13
- 52 Week High
- HYI $12.24
- TVRD $34.31
- Technical
- Relative Strength Index (RSI)
- HYI 53.23
- TVRD N/A
- Support Level
- HYI $11.76
- TVRD N/A
- Resistance Level
- HYI $11.86
- TVRD N/A
- Average True Range (ATR)
- HYI 0.10
- TVRD 0.00
- MACD
- HYI 0.00
- TVRD 0.00
- Stochastic Oscillator
- HYI 67.50
- TVRD 0.00
About HYI Western Asset High Yield Defined Opportunity Fund Inc.
Western Asset High Yield Defined Opps. is a non-diversified, limited-term, closed-end management investment company. The company's investment objective is to provide high income and seek capital appreciation. It invests a majority of its net assets in a portfolio of high-yield corporate fixed-income securities issued or originated by U.S. or foreign public or private corporations and other business entities, with varying maturities.
About TVRD Tvardi Therapeutics Inc. Common Stock
Tvardi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development of novel, oral small molecule therapies targeting STAT3 to treat fibrosis-driven diseases. Its key product candidate, TTI-101, is in Phase 2 clinical development for the treatment of idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC). Its second product candidate, TTI-109, is structurally related to, yet chemically distinct from, TTI-101 and is designed to enhance the ability to target STAT3.